LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma

Status:
Terminated

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

The primary purpose of the Phase II CLGX818X2102 study is to assess the anti-tumor activity of LGX818 in combination with selected agents.

Phase 2

Array BioPharma